Hyperlipidemia Drugs Market Report 2026

Hyperlipidemia Drugs Market Overview

• Hyperlipidemia Drugs market size has reached to $24.74 billion in 2025 • Expected to grow to $32.31 billion in 2030 at a compound annual growth rate (CAGR) of 5.4% • Growth Driver: Increasing Prevalence Of Cardiovascular Diseases Fueling The Growth Of The Market Due To Rising Risk Factors • Market Trend: Dual-Action Drugs Simplify Management of Cholesterol and Triglycerides • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Hyperlipidemia Drugs Market?

Hyperlipidemia drugs are medications used to lower high levels of lipids, such as cholesterol and triglycerides, in the blood. These drugs work through various mechanisms, such as decreasing cholesterol production, enhancing its removal, or reducing fat absorption. Hyperlipidemia drugs help reduce the risk of cardiovascular diseases by managing abnormal lipid profiles. The main drug classes of hyperlipidemia drugs are statins, bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, proprotein convertase subtilisin or kexin type 9 (PCSK9) inhibitors, combinations, and miscellaneous. Statins are a class of medications that lower cholesterol levels in the blood by inhibiting the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, which plays a key role in cholesterol synthesis in the liver. These drugs are administered through various routes, including oral, parenteral, and other routes of administration, and distributed through various channels such as hospital pharmacies, online pharmacies, and retail pharmacies, serving a wide range of end users, such as hospitals, clinics, and others.

What Is The Hyperlipidemia Drugs Market Growth Forecast?

The hyperlipidemia drugs market size is expected to see strong growth in the next few years. It will grow to $32.31 billion in 2030 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to launch of novel pcsk9 inhibitors and inclisiran, growth of combination therapies, rising awareness of personalized medicine, increasing healthcare expenditure on cardiovascular management, integration of digital health monitoring tools. Major trends in the forecast period include rising adoption of statins and pcsk9 inhibitors, growth in combination therapy usage for hyperlipidemia management, increasing awareness about cardiovascular disease prevention, expansion of hospital and retail pharmacy channels, rising demand for personalized lipid-lowering treatments.

Global Hyperlipidemia Drugs Market Segmentation

1) By Drug Class: Statins, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, Fibric Acid Derivatives, Proprotein Convertase Subtilisin Or Kexin Type 9 (PCSK9) Inhibitors, Combination, Miscellaneous 2) By Route Of Administration: Oral, Parenteral, Other Route Of Administrations 3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies 4) By End User: Hospitals, Clinics, Other End Users Subsegments: 1) By Statins: Atorvastatin, Rosuvastatin, Simvastatin, Pravastatin, Fluvastatin, Lovastatin, Pitavastatin 2) By Bile Acid Sequestrants: Cholestyramine, Colesevelam, Colestipol 3) By Cholesterol Absorption Inhibitors: Ezetimibe, Ezetimibe-Simvastatin Combination 4) By Fibric Acid Derivatives: Fenofibrate, Gemfibrozil, Bezafibrate, Ciprofibrate 5) By Proprotein Convertase Subtilisin Or Kexin Type 9 (PCSK9) Inhibitors: Evolocumab, Alirocumab, Inclisiran 6) By Combination: Statin + Ezetimibe, Statin + Niacin, Statin + Omega-3, Statin + Bile Acid Sequestrant, Fixed-Dose Combinations (FDCs) Of Statins + Antihypertensives 7) By Miscellaneous: Niacin (Nicotinic Acid), Omega-3 Fatty Acids (EPA/DHA), Lomitapide, Mipomersen, Bempedoic Acid

What Is The Driver Of The Hyperlipidemia Drugs Market?

The increasing prevalence of cardiovascular diseases is expected to propel the growth of the hyperlipidemia drugs market going forward. Cardiovascular diseases refer to a group of disorders affecting the heart and blood vessels, including conditions such as coronary heart disease, heart failure, stroke, and hypertension. The increasing prevalence of cardiovascular diseases is primarily attributed to poor diet, as the excessive consumption of saturated fats, trans fats, added sugars, and sodium contributes to high blood pressure, obesity, and elevated cholesterol levels. Hyperlipidemia drugs help manage cardiovascular diseases by effectively lowering harmful cholesterol and triglyceride levels, making them vital for heart health. They simplify treatment with advanced therapies, reducing the risk of complications and improving patient outcomes. For instance, in October 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, in 2023, cardiovascular disease claimed 919,032 lives, accounting for one in every three deaths. Coronary heart disease remained the most prevalent form of heart disease, and notably, about one in six deaths from cardiovascular diseases occurred among adults younger than 65 years. Therefore, the increasing prevalence of cardiovascular diseases is driving the growth of the hyperlipidemia drugs industry.

Key Players In The Global Hyperlipidemia Drugs Market

Major companies operating in the hyperlipidemia drugs market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Amgen Inc., Takeda Pharmaceutical Company Limited, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., STADA Arzneimittel AG, Aurobindo Pharma Ltd., Zydus Lifesciences Limited, Lupin Limited, Glenmark Pharmaceuticals Ltd.

Global Hyperlipidemia Drugs Market Trends and Insights

Major companies operating in the hyperlipidemia drugs market are focusing on developing advanced therapies, such as combination therapies, to boost effectiveness and simplify treatment for better heart health. Combination therapies refer to treatments that use two or more different drugs together in one regimen to target a disease more effectively than a single drug alone. For instance, in June 2024, Daewoong Bio Inc., a South Korea-based pharmaceutical company, launched CRA-TG Soft Capsule, a combination drug that combines rosuvastatin with omega-3 fatty acids to treat hyperlipidemia in patients. Rosuvastatin reduces cholesterol production in the liver, lowering harmful low-density lipoprotein (LDL) levels in the blood, while omega-3 fatty acids are used as a dietary supplement to reduce triglyceride levels in patients with high triglycerides. This product utilizes patented multi-layer capsule coating technology to enhance ingredient stability and tolerability while retaining a standard capsule size.

What Are Latest Mergers And Acquisitions In The Hyperlipidemia Drugs Market?

In July 2025, Eli Lilly and Company, a US-based pharmaceutical company, acquired Verve Therapeutics Inc. for an undisclosed amount. With this acquisition, Eli Lilly aims to advance one-time gene-editing therapies that target the root causes of cardiovascular disease, potentially transforming treatment from ongoing medication to lasting solutions that significantly lower cardiovascular risk. Verve Therapeutics Inc. is a US-based clinical-stage biotechnology company developing gene-editing therapies to treat hyperlipidemia.

Regional Insights

North America was the largest region in the hyperlipidemia drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Hyperlipidemia Drugs Market?

The hyperlipidemia drugs market consists of sales of niacin, lomitapide, mipomersen, bempedoic acid, probucol, fibrates, and omega-3 fatty acid products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Hyperlipidemia Drugs Market Report 2026?

The hyperlipidemia drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the hyperlipidemia drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.